Blepharoptosis
Blepharoptosis
Keywords:
ptosis, blepharoptosis, eyelid drooping, myasthenia gravisAbstract
Ptosis (blepharoptosis) can occur at any age and may affect one or both eyes. Its causes range from issues related to the eyelid itself to abnormalities in associated nerves. In some cases, ptosis may result from genetic disorders, which are increasingly being identified. Ptosis can be classified based on its causes into mechanical ptosis, aponeurotic ptosis, myogenic ptosis, ptosis resulting from neuromuscular junction disorders, and neurogenic ptosis. Additionally, it can be categorized as unilateral or bilateral, or based on the age of onset as congenital or acquired. The treatment of ptosis depends on the cause. Most patients require treatment focused on the eyelid area, which includes both surgical and non-surgical methods. Ptosis can cause cosmetic concerns, impair vision, or sometimes be a symptom of a serious, life-threatening medical condition. Therefore, understanding all potential causes of ptosis is essential for proper patient management, including proper referral
References
Latting MW, Huggins AB, Marx DP, Giacometti JN. Clinical evaluation of blepharoptosis: distinguishing age-related ptosis from masquerade conditions. Semin Plast Surg 2017;31(1):5-16.
Díaz-Manera J, Luna S, Roig C. Ocular ptosis: Differential diagnosis and treatment. Curr Opin Neurol 2018;31(5):618-27.
Gao T, Guo Y, Rokohl AC, Fan W, Lin M, Ju S, et. al. Racial and sexual differences of eyebrow and eyelid morphology: three-dimensional analysis in young Caucasian and Chinese populations. Quant Imaging Med Surg 2025;15(1):882-97.
Rana K, Beecher MB, Caltabiano C, Zhao Y, Verjans J, Selva D. Normal periocular anthropometric measurements in an Australian population. Int Ophthalmol 2023;43(8):2695-701.
Murchison AP, Sires BA, Jian-Amadi A. Margin reflex distance in different ethnic groups. Arch Facial Plast Surg 2009;11(5):303-5.
Marenco M, Macchi I, Macchi I, Galassi E, Massaro-Giordano M, Lambiase A. Clinical presentation and management of congenital ptosis. Clin Ophthalmol 2017;11(2):453-63.
Li F, Chai P, Fan J, Wang X, Lu W, Li J, et al. A novel FOXL2 mutation implying blepharophimosis-ptosis-epicanthus inversus syndrome type I. Cell Physiol Biochem 2018;45(1):203-11.
Heighton JN, Brady LI, Newman MC, Tarnopolsky MA. Clinical and demographic features of chronic progressive external ophthalmoplegia in a large adult-onset cohort. Mitochondrion 2019;44(1):15-9.
van der Sluijs BM, Lassche S, Knuiman GJ, Kusters B, Heerschap A, Hopman M, et al. Involvement of pelvic girdle and proximal leg muscles in early oculopharyngeal muscular dystrophy. Neuromuscul Disord 2017;27(12):1099-105.
Choi SH, Yang HK, Hwang JM, Park KS. Ocular findings of myotonic dystrophy type 1 in the Korean population. Graefes Arch Clin Exp Ophthalmol 2016;254(6):1189-93.
Gilhus NE. Myasthenia gravis. N Engl J Med 2016;375(26):2570-81.
Kamarajah SK, Sadalage G, Palmer J, Carley H, Maddison P, Sivaguru A. Ocular presentation of myasthenia gravis: A natural history cohort. Muscle Nerve 2018;57(4):622-7.
O'Hare M, Doughty C. Update on ocular myasthenia gravis. Semin Neurol 2019;39(6):749-60.
Narayanaswami P, Sanders DB, Wolfe G, Benatar M, Cea G, Evoli A, et. al. International consensus guidance for management of myasthenia gravis: 2020 update. Neurology 2021;96(3):114-22.
Pacella E, Mipatrini D, Pacella F, Amorelli G, Bottone A, Smaldone G, et. al. Suspensory materials for surgery of blepharoptosis: A systematic review of observational studies. PLoS One 2016;11(9):e0160827. doi: 10.1371/journal.pone.0160827
Kim CY, Yoon JS, Bae JM, Lee SY. Prediction of postoperative eyelid height after frontalis suspension using autogenous fascia lata for pediatric congenital ptosis. Am J Ophthalmol 2012;153(2):334-42.e2. doi: 10.1016/j.ajo.2011.07.023
Repp DJ, Rubinstein TJ, Sires BS. Role of algorithm-based levator aponeurectomy in small-incision external ptosis surgery for involutional ptosis. JAMA Facial Plast Surg 2017;19(6):490-5.
Bacharach J, Lee WW, Harrison AR, Freddo TF. A review of acquired blepharoptosis: Prevalence, diagnosis, and current treatment options. Eye (Lond) 2021;35(9):2468-81.
Newland M, Eberly H, Ma C, Lighthall JG. The use of oxymetazoline 0.1% ophthalmic solution for acquired blepharoptosis: A systematic review. Laryngoscope 2025;135(1):8-14.
Goldberg DJ, Andriessen A, Gold M, Lolis MS, Marchbein S, Nestor MS, et. al. A review of nonsurgical facial rejuvenation and the role of oxymetazoline hydrochloride ophthalmic solution, 0.1% in periorbital revitalization. J Cosmet Dermatol 2024;23(4):1122-30.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Buddhchinaraj Phisanulok Hospital
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
